Table 3.
Multivariate logistic regression analysis of factors for ALN pCR in the retrospective series.
| Variable | Coefficient | SE | Wald | OR (95% CI) | P value |
| Age∗ | −0.391 | 0.205 | 3.647 | 0.677 (0.453–1.010) | 0.056 |
| Clinical T stage | |||||
| T2 | −0.804 | 0.466 | 2.975 | 0.447 (0.179–1.116) | 0.085 |
| T3 | −0.598 | 0.470 | 1.622 | 0.550 (0.219–1.381) | 0.203 |
| T4 | −1.135 | 0.500 | 5.153 | 0.321 (0.121–0.856) | 0.023 |
| Pathological type Others† | −0.292 | 0.515 | 0.322 | 0.747 (0.272–2.049) | 0.570 |
| Histologic grade | |||||
| II | −0.180 | 0.629 | 0.082 | 1.106 (0.444–1.174) | 0.775 |
| III | 0.029 | 0.244 | 1.302 | 1.114 (0.658–1.710) | 0.254 |
| Primary tumor response CR | −1.762 | 0.231 | 58.150 | 0.189 (0.123–0.292) | <0.001 |
| ER positive | −0.635 | 0.284 | 4.991 | 0.530 (0.304–0.925) | 0.025 |
| PR positive | −0.031 | 0.284 | 0.012 | 0.970 (0.555–1.694) | 0.915 |
| HER2 positive | 0.331 | 0.231 | 2.047 | 1.392 (0.885–2.189) | 0.153 |
Continuous variables.
Others, invasive lobular carcinoma, invasive papillary carcinoma, mucinous carcinoma. CR: Complete response; CI: Confidence interval; ER: Estrogen receptor; HER2: Human epidermal growth factor receptor 2; OR: Odds ratio; Clinical T stage: Clinical tumor stage; PR: Progesterone receptor; pCR: Pathological complete response; SE: Standard error.